Vericel Corporation (VCEL)

Description: Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.

---

Keywords: Medicine Biotechnology Biopharmaceutical Stem Cell Cell Therapy Heart Failure Burns Knee Cartilage Cardiomyopathy Myopathy Osteochondritis Dissecans Severe Diseases

---

Home Page: vcel.com

VCEL Technical Analysis

64 Sidney Street
Cambridge, MA 02139
United States
Phone: 617 588 5555

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)